Molecule Information
General Information of the Molecule (ID: Mol02209)
Type(s) of Resistant Mechanism of This Molecule
EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Drug
Clinical Trial Drug(s)
1 drug(s) in total
Afeletecan
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Colorectal cancer | [1] | |||
Resistant Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
Resistant Drug | Afeletecan | |||
Molecule Alteration | Up-regulation | Interaction |
||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | SW480 cells | Colon | Homo sapiens (Human) | CVCL_0546 |
CCD18-Co cells | Colon | Homo sapiens (Human) | CVCL_2379 | |
In Vivo Model | NOD/SCID mice model | Mus musculus | ||
Experiment for Molecule Alteration |
Knockdown assay; Overexpression assay; qRT-PCR; Western bloting analysis; RNA-seq; RIP experiments assay; ChIP assay; RNA pull down assay | |||
Experiment for Drug Resistance |
Soft agar assay | |||
Mechanism Description | Overall, recent clinical trials using topoisomerase inhibitors coupled with our findings of RAMS11-dependent regulation of TOP2alpha supports the potential use of RAMS11 as a biomarker and therapeutic target for mCRC. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.